Page last updated: 2024-11-07

cositecan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

cositecan: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID148202
CHEMBL ID1997373
CHEBI ID177492
SCHEMBL ID2315201
MeSH IDM0576755

Synonyms (42)

Synonym
(19s)-19-ethyl-19-hydroxy-10-(2-trimethylsilylethyl)-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
CHEBI:177492
cositecan
nsc-710270
NCI60_038797
karenitecin
7-trimethylsilylethylcamptothecin
nsc710270
cositecan (usan)
203923-89-1
D09327
karenitecin (tn)
1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-11-(2-trimethylsilyl)ethyl)-, (4s)-
bnp1350
unii-24r60nvc41
(4s)-4-ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1,12-dihydro-14h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h)-dione
24r60nvc41 ,
bnp-1350
cositecan [usan:inn]
bnp 1350
db 172
DB05806
cositecan [who-dd]
cositecan [mi]
1h-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy- 11-(2- (trimethylsilyl)ethyl)-, (4s)-
(4s)-4-ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1,12-dihydro-14h- pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4h)-dione
cositecan [usan]
karentecin
cositecan [inn]
SCHEMBL2315201
CHEMBL1997373
DTXSID90174340
HY-14812
CS-0003573
karenitecin (cositecan)
(s)-4-ethyl-4-hydroxy-11-(2-(trimethylsilyl)ethyl)-1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione.
Q27095699
POADTFBBIXOWFJ-VWLOTQADSA-N
cositecan;bnp 1350
MS-28131
1h-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4h,12h)-dione, 4-ethyl-4-hydroxy-11-[2-(trimethylsilyl)ethyl]-, (4s)-
AKOS040741401

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"Disappearance of the lactone form from the plasma was biexponential with a mean distribution half-life of 57."( Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates.
Aleksic, A; Berg, SL; Blaney, SM; Dauser, R; Hausheer, F; Kerr, JZ; McGuffey, L; Nuchtern, JG; Thompson, PA, 2004
)
0.32

Compound-Compound Interactions

ExcerptReferenceRelevance
" Future karenitecin clinical trials should include studies to monitor or evaluate the effects of these potential drug interactions on the overall toxicity of karenitecin when used in combination with other drugs."( Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development.
Hausheer, FH; Madden, T; Newman, RA; Smith, JA, 2003
)
0.32

Bioavailability

ExcerptReferenceRelevance
"The novel camptothecin derivative BNP1350 (7-[2-trimethylsilyl)ethyl]-20(S)-camptothecin), also known as Karenitecin, has been developed for superior oral bioavailability and increased lactone stability."( Novel camptothecin derivative BNP1350 in experimental human ovarian cancer: determination of efficacy and possible mechanisms of resistance.
Boven, E; Hausheer, FH; Pinedo, HM; Schlüper, HM; Van Hattum, AH, 2002
)
0.31

Dosage Studied

ExcerptRelevanceReference
"0 mg/kg per dose via intraperitoneal injection for a period of 10 consecutive days, which is the dosage lethal to 10% of treated animals."( Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice.
Bigner, DD; Friedman, HS; Hausheer, F; Keir, ST; Lawless, AA, 2001
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyranoindolizinoquinoline
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's17 (89.47)29.6817
2010's2 (10.53)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.77

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.77 (24.57)
Research Supply Index3.26 (2.92)
Research Growth Index4.85 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.77)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (25.00%)5.53%
Reviews1 (5.00%)6.00%
Case Studies1 (5.00%)4.05%
Observational0 (0.00%)0.25%
Other13 (65.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]